載入中
NASDAQHealthcareDrug Manufacturers - General
最新資料
US$2.92
−US$0.04 · -1.35%
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
前收盤價
US$2.92
−US$0.04 · -1.35%
盤中時間採用ET。市場資料可能有所延遲。
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
日內區間
目前US$2.92
52週區間
目前US$2.92
盤中時間採用ET。市場資料可能有所延遲。
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
日內區間
目前US$2.92
52週區間
目前US$2.92
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3025.3萬 USD | 5659萬 USD | 4674.3萬 USD | 3803.4萬 USD | 3131.7萬 USD |
| 銷貨成本 | 1522.2萬 USD | 1668.9萬 USD | 1568.1萬 USD | 1079.7萬 USD | 363.4萬 USD |
| 毛利 | 1503.1萬 USD | 3990.1萬 USD | 3106.2萬 USD | 2723.7萬 USD | 2768.3萬 USD |
| 研究與開發 | 2071萬 USD | 964.1萬 USD | 1274.6萬 USD | 905.4萬 USD | 920.1萬 USD |
| 銷售、一般及管理費用 | 2.67億 USD | 1.19億 USD | 1.2億 USD | 6489.5萬 USD | 5058.2萬 USD |
| 營業費用 | 2.87億 USD | 1.23億 USD | 1.36億 USD | 7787.1萬 USD | 6352.1萬 USD |
| 利息支出 | 1145.9萬 USD | 196.3萬 USD | 106.8萬 USD | 960.4萬 USD | 1176.4萬 USD |
| 折舊和攤銷 | 462.3萬 USD | 404.6萬 USD | 414.6萬 USD | 396.1萬 USD | 377.9萬 USD |
| 營業利益 | −2.72億 USD | −8339.6萬 USD | −1.05億 USD | −5063.4萬 USD | −3583.8萬 USD |
| 淨利 | −3.59億 USD | −7280.7萬 USD | −1.14億 USD | −2336.4萬 USD | −8842.4萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI119.52萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF41.89萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC7.08萬0.01%13.17億 USD0.60%US$183+0.11%
Avantis Total Equity Markets ETF 1AVTM236.8—7.94億 USD0.23%US$55.6085+0.56%
Dimensional - US Core Equity Market ETFDFAU195.360.00%131.2億 USD0.12%US$53.43+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis Total Equity Markets ETF 1AVTMDimensional - US Core Equity Market ETFDFAUAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
